S Antila

Summary

Country: Finland

Publications

  1. ncbi request reprint Site dependent bioavailability and metabolism of levosimendan in dogs
    S Antila
    Orion Pharma, PO Box 65, 02101, Espoo, Finland
    Eur J Pharm Sci 9:85-91. 1999
  2. ncbi request reprint Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin
    S Antila
    Orion Pharma, Research Centre, Espoo, Finland
    Eur J Clin Pharmacol 56:705-10. 2000
  3. ncbi request reprint Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure
    P Poder
    Cardiovascular Projects, Research Centre, Orion Pharma, Espoo, Finland
    Int J Clin Pharmacol Ther 41:365-73. 2003
  4. ncbi request reprint Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique
    H Heikkinen
    Research Centre, Orion Corporation Orion Pharma, Espoo, Finland
    Eur J Clin Pharmacol 56:821-6. 2001
  5. ncbi request reprint Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure
    M Kivikko
    Orion Pharma, Cardiovascular Projects, Espoo, Finland
    Int J Clin Pharmacol Ther 40:465-71. 2002
  6. ncbi request reprint Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules
    H Kortejärvi
    Orion Pharma, PO Box 65, FIN 02101, Espoo, Finland
    Int J Pharm 241:87-95. 2002

Detail Information

Publications6

  1. ncbi request reprint Site dependent bioavailability and metabolism of levosimendan in dogs
    S Antila
    Orion Pharma, PO Box 65, 02101, Espoo, Finland
    Eur J Pharm Sci 9:85-91. 1999
    ..The bacteria or enzymes responsible for the metabolism of levosimendan are located in the lower parts of the gastrointestinal tract...
  2. ncbi request reprint Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin
    S Antila
    Orion Pharma, Research Centre, Espoo, Finland
    Eur J Clin Pharmacol 56:705-10. 2000
    ..To study the effects of possible interactions between levosimendan and warfarin on pharmacokinetics and pharmacodynamics. Furthermore, the effects of levosimendan on blood coagulation were investigated...
  3. ncbi request reprint Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure
    P Poder
    Cardiovascular Projects, Research Centre, Orion Pharma, Espoo, Finland
    Int J Clin Pharmacol Ther 41:365-73. 2003
    ..To assess the pharmacokinetic-pharmacodynamic (PK-PD) interrelations after a 6-hour continuous infusion and a 2 mg single oral dose of levosimendan in patients with congestive heart failure (CHF)...
  4. ncbi request reprint Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique
    H Heikkinen
    Research Centre, Orion Corporation Orion Pharma, Espoo, Finland
    Eur J Clin Pharmacol 56:821-6. 2001
    ..In comparison with a crossover design, the simultaneous i.v. and oral administration made it possible to minimise intra-individual variation, sample size and the duration of the study and still obtain accurate pharmacokinetic data...
  5. ncbi request reprint Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure
    M Kivikko
    Orion Pharma, Cardiovascular Projects, Espoo, Finland
    Int J Clin Pharmacol Ther 40:465-71. 2002
    ..The aims of the present study were to determine the pharmacokinetics and hemodynamic effects of levosimendan and its metabolites during and after a 24-hour levosimendan infusion...
  6. ncbi request reprint Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules
    H Kortejärvi
    Orion Pharma, PO Box 65, FIN 02101, Espoo, Finland
    Int J Pharm 241:87-95. 2002
    ....